Aids

Background

AIDS (Acquired Immunodeficiency Syndrome) is a chronic, potentially life-threatening condition caused by the Human Immunodeficiency Virus (HIV). HIV targets and destroys CD4+ T-cells, which are crucial components of the immune system. Without effective treatment, the progressive loss of these cells leads to severe immunodeficiency, making the body vulnerable to opportunistic infections and certain cancers, which collectively define the syndrome known as AIDS. The condition was first recognized in the early 1980s, leading to significant public health efforts and research initiatives, such as the Multicenter AIDS Cohort Study Furthermore, the potential for misclassification of cases, such as including individuals with average susceptibility, can diminish power, although studies have successfully identified known large-effect variants likeCCR5D32 homozygosity even with imperfect imputation.^[1] The absence of control groups specifically enriched for proven or suspected HIV-1 resistance also limits the power to uncover novel genetic associations.

Replication of genetic findings is a critical step, but it faces challenges stemming from differences in study design and population characteristics. Replication efforts can be hampered by variations in HIV exposure types, such as sexual transmission versus drug injection, or differing degrees of exposure across cohorts.^[2]When exact single nucleotide polymorphisms (SNPs) are not available for direct replication, researchers may rely on proxy SNPs or less stringent “gene region” replication approaches, which might not fully capture the original association signal.^[3] This can lead to situations where the most robustly replicated SNPs are not the strongest signals from initial discovery phases, suggesting that some initial suggestive findings may not represent true associations or that studies are still underpowered for definitive validation.^[2] Rigorous quality control measures are crucial in large genetic datasets to mitigate spurious associations arising from small systematic differences in sample handling or genotyping, requiring a careful balance between stringent and lenient SNP exclusion criteria and often visual inspection of cluster plots.^[4]

Population Heterogeneity and Generalizability

The genetic architecture influencing aids susceptibility can vary significantly across human populations, posing challenges for the generalizability of findings. Ancestry-specific genetic effects are evident, as demonstrated by a lack of concordance in the direction of effect across diverse populations and distinct clustering in principal component analysis plots, suggesting that some associations may be specific to certain ancestral backgrounds.^[5] While multi-ancestral meta-analyses aim to increase statistical power by combining data from different groups, the high degree of genetic admixture within some populations necessitates careful stratification to avoid confounding and ensures that results are interpreted within their specific ancestral context.^[2]Cohort biases further impact the generalizability of genetic discoveries. Historically, many AIDS cohorts in Western countries were predominantly male, whereas more recent studies, such as those in Botswana, may have a greater emphasis on female participants.^[3] This demographic imbalance, coupled with the focus on specific risk groups (e.g., actively gay males, hemophiliacs, persons who inject drugs), means that findings from one cohort may not be directly transferable to other populations or risk profiles.^[3]To achieve a more comprehensive understanding of the genetic determinants of aids, future research must expand to include broader representation from diverse African regions, various ethnic groups, and underrepresented demographics such as men and children.^[3]

Unaccounted Factors and Remaining Knowledge Gaps

Current genetic association studies, while powerful, often do not fully account for critical non-genetic factors that play a substantial role in HIV-1 transmission and progression. Host microbiome composition, epigenetic modifications, and complex environmental and social determinants are known to influence disease outcomes but are frequently omitted from genetic analyses.^[3]This omission means that the complete landscape of factors contributing to aids susceptibility and disease trajectory is not yet fully elucidated, potentially leading to an incomplete understanding of the biological mechanisms underlying observed genetic associations.

A significant portion of the heritability for complex traits like aids susceptibility remains unexplained, highlighting a persistent knowledge gap in our understanding of host genetic determinants. To address this, future research requires an integrated approach that incorporates multiple kinds of genome-level data beyond standard genomic DNA, including epigenetic data, transcriptome analyses, and siRNA screens.^[3] Furthermore, advanced resequencing strategies are essential for identifying rare causal genetic variants that may be missed by conventional GWAS methods, which primarily focus on common variants.^[3] By combining these diverse data modalities and explicitly considering non-genetic factors, future study designs can foster a more comprehensive understanding of how host genome variability influences HIV-1 acquisition, progression, and transmission on both regional and global scales.^[3]

Variants

The genetic landscape influencing the progression of HIV-1 to AIDS is complex, involving numerous variants that modulate immune responses, cellular functions, and viral interactions. Understanding these genetic variations provides insights into the diverse clinical outcomes observed among individuals infected with HIV-1. These variants can affect the speed at which the virus replicates, the strength of the host’s immune defense, and the overall progression of the disease.

One of the most significant genetic factors associated with HIV-1 progression is the rs2395029 variant within the HCP5 (HLA Complex P5) pseudogene. HCP5 is located in the Major Histocompatibility Complex (MHC) region on chromosome 6, which is crucial for the adaptive immune system’s ability to recognize and respond to pathogens. The rs2395029 variant is in strong linkage disequilibrium with HLA-B*5701, an allele known to confer significant protection against HIV-1, leading to slower disease progression and lower viral loads. Research indicates that the protective effects of this locus on HIV disease progression are primarily mediated by its impact on early viral control, suggesting a critical role in the initial stages of the immune response to HIV.^[6]This genetic association highlights how variations in immune-related genes can profoundly alter an individual’s capacity to manage HIV-1 infection and delay the onset of clinical AIDS.^[7] Beyond the MHC region, other variants influence immune cell function and signaling pathways that are critical to HIV pathogenesis. The rs4118325 variant is associated with PRMT6(Protein Arginine Methyltransferase 6), an enzyme involved in protein arginine methylation, a post-translational modification that can regulate gene expression and potentially impact viral replication. Similarly,rs6467710 , located in DGKI (Diacylglycerol Kinase I), may affect T cell activation and proliferation, as DGKI plays a role in diacylglycerol signaling, which is essential for immune cell responses. Alterations in this pathway could impact the immune system’s ability to control HIV.^[8] Another variant, rs1020064 , is linked to TGFBRAP1(TGF-beta Receptor Associated Protein 1), which modulates the transforming growth factor-beta (TGF-beta) signaling pathway. TGF-beta is a potent immunoregulator that can suppress immune responses, and variations in its pathway could affect the balance of inflammation and immune suppression, both of which are critical in HIV disease. Additionally,rs1522232 , associated with SOX5 (SRY-Box Transcription Factor 5) and its antisense RNA SOX5-AS1, can influence immune cell development and differentiation, thereby modulating the host’s response to HIV infection.^[7] Further variants contribute to the host-pathogen interaction through their roles in cellular structure, transcriptional regulation, and non-coding RNA functions. The rs11884476 variant in PARD3B (Par-3 Family Cell Polarity Regulator Beta) could impact cell polarity and migration, processes vital for immune cell trafficking and maintaining tissue barriers against viral spread. The rs10800098 variant, associated with RXRG (Retinoid X Receptor Gamma), may influence the expression of genes involved in immune regulation and metabolism, as RXRG is a nuclear receptor that controls various cellular processes.^[3] The rs1360517 variant, linked to MPDZ (Multiple PDZ Domain Protein), might affect cell junction organization and signal transduction, which are crucial for cellular integrity and proper immune cell interactions. Non-coding RNA genes also play regulatory roles; rs4118325 is associated with LINC01661, a long intergenic non-coding RNA, and rs1556032 is linked to NFIB-AS1, an antisense RNA that can modulate the expression of the NFIB transcription factor, impacting immune cell function. Pseudogenes, such as those associated with rs3108919 (RPS20P23 and RNU4-83P), are non-protein-coding but can still influence gene regulation or serve as markers for nearby functional variants relevant to HIV/AIDS.^[2]

Key Variants

RS ID	Gene	Related Traits
rs2395029	HCP5	aids HIV-1 infection psoriasis drug-induced liver injury LCN2/PGLYRP1 protein level ratio in blood
rs4118325	LINC01661 - PRMT6	aids
rs11884476	PARD3B	aids
rs6467710	DGKI	aids
rs10800098	RXRG	aids
rs1360517	PRDX1P1 - MPDZ	aids
rs1020064	TGFBRAP1	aids
rs1522232	SOX5, SOX5-AS1	aids
rs3108919	RPS20P23 - RNU4-83P	aids
rs1556032	NFIB-AS1	aids body height size

Definition and Core Terminology

Acquired Immunodeficiency Syndrome (AIDS) represents the advanced stage of infection with the Human Immunodeficiency Virus (HIV).^[9]The term HIV/AIDS is frequently used to encompass both the viral infection and its symptomatic, immunodeficient manifestation.^[9]This progression from initial HIV infection to clinical AIDS is characterized by a significant decline in the body’s immune function, rendering individuals susceptible to opportunistic infections and certain cancers.^[10]Essential terminology surrounding AIDS also includes antiretroviral therapy (ART) or antiretrovirals (ARV), which are critical pharmaceutical interventions designed to suppress the HIV virus, manage the infection, and prevent its progression to AIDS.^[9]Early epidemiological research, such as the Multicenter AIDS Cohort Study, was instrumental in establishing the foundational characteristics and understanding the natural history of the condition.^[11]

Clinical Classification and Diagnostic Criteria

The diagnosis and classification of AIDS are guided by standardized systems developed by major public health organizations to ensure consistent surveillance and patient management.^[12]A cornerstone of this framework is the 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, issued by the Centers for Disease Control and Prevention (CDC).^[12]This system integrates both clinical criteria, such as the presence of specific AIDS-defining opportunistic infections or malignancies, and immunological criteria, primarily a severe reduction in CD4 T-cell count.^[13]The World Health Organization (WHO) similarly provides global guidelines that influence international standards for defining and tracking the HIV/AIDS epidemic.^[14]

Biomarkers and Disease

The trajectory of HIV infection toward AIDS is quantitatively monitored using specific biomarkers and approaches.^[10] Key diagnostic and monitoring criteria include the CD4 T-cell count, which is measured in cells/µL and serves as a crucial indicator of immune system health.^[13] Another vital biomarker is HIV-1 RNA, commonly referred to as viral load, which quantifies the amount of circulating virus in copies/mL.^[13]These objective measurements, alongside clinical observations, are fundamental in determining the stage of HIV disease and defining the onset of AIDS, which is typically characterized by CD4 T-cell counts falling below established thresholds.^[13]Research also focuses on the rate of HIV-1 disease progression to clinical AIDS, examining the temporal dynamics from initial infection to the development of AIDS-defining conditions.^[10]

Clinical Spectrum and Associated Phenotypes

AIDS is characterized by a broad and diverse spectrum of clinical manifestations, as outlined by the 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.^[12]The progression to clinical AIDS can involve numerous phenotypes beyond opportunistic infections, reflecting the systemic impact of the underlying immunodeficiency. For instance, cardiovascular complications like carotid atherosclerosis have been observed in HIV-infected individuals, particularly men.^[15]Furthermore, treatment-related clinical presentations, such as hepatotoxicity induced by antiretrovirals alone or in combination with anti-tuberculosis drugs, represent significant complications that require clinical attention.^[16] The phenotypic diversity also extends to specific infections, where individuals may exhibit resistance to TST/IGRA conversion, indicating varying immune responses to pathogens like Mycobacterium tuberculosis.^[17] This heterogeneity in clinical presentation is influenced by inter-individual variation and can also be modulated by factors such as age and sex, which are often adjusted for in clinical analyses.^[18]

Key Immunological and Biochemical Markers

The diagnosis and monitoring of AIDS heavily rely on specific immunological and biochemical markers, providing objective measures of disease status and progression. A critical biomarker is the CD4 T-cell count, which serves as a primary indicator of HIV-1 disease progression; a decline below 350 cells/µL is a significant prognostic threshold.^{[6], [18]}Alongside CD4 T-cell counts, HIV-1 RNA levels, commonly known as viral load, measured in copies/mL, are essential for assessing disease activity and the effectiveness of treatment, with the HIV-1 set point representing a stable viral load after acute infection.^{[6], [18]}Beyond these core markers, a comprehensive assessment often includes a wide array of pretreatment laboratory parameters. These encompass absolute neutrophil counts, absolute basophil counts, absolute eosinophil counts, absolute lymphocyte counts, absolute monocyte counts, and platelet counts (cells × 10^3/µL); liver enzymes such as ALT, alkaline phosphatase, and AST (U/L); renal function indicators like blood urea nitrogen and creatinine (mg/dL); metabolic markers including fasting and nonfasting glucose, total bilirubin, total cholesterol, HDL-C, LDL-C, and triglycerides (mg/dL); and electrolytes such as carbon dioxide/bicarbonate, chloride, potassium, and sodium (mmol/L), along with hematocrit (g/dL or %).^[18] These objective measurements are crucial for identifying sub-phenotypes, guiding therapeutic decisions, and evaluating treatment efficacy.

Disease Progression and Genetic Determinants

The progression of HIV-1 infection to clinical AIDS is highly variable, influenced by numerous factors, including the incubation period, which can differ significantly among individuals.^{[7], [19]}Clinical phenotypes of disease progression are often defined by specific immunological criteria, such as a sustained drop of CD4 T-cell counts below 350 cells/µL, or by clinical intervention, such as the initiation of combination antiretroviral therapy (cART) when CD4 T-cell counts fall below 500 cells/µL.^[6] This variability also includes “rapid progressors” who may not achieve a stable viral load plateau.^[6]Research employing genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS) has elucidated the role of human genetic variants in influencing the rate of disease progression and various clinical and laboratory phenotypes.^{[7], [18]} For instance, a specific locus at 1q41has been identified through a multistage GWAS as being associated with the rate of HIV-1 disease progression to clinical AIDS.^[7]These genetic insights provide valuable prognostic indicators and contribute to understanding the clinical correlations observed in the heterogeneous course of AIDS.

Causes of AIDS

The development and progression of Acquired Immunodeficiency Syndrome (AIDS) are influenced by a complex interplay of host genetic factors, environmental exposures, and their interactions. While the Human Immunodeficiency Virus (HIV) infection is the primary prerequisite for AIDS, the rate of HIV acquisition and subsequent disease progression varies significantly among individuals due to a multitude of biological and external factors. Research employing genome-wide association studies (GWAS) has illuminated many of these contributing elements, particularly host genetic determinants.

Host Genetic Predisposition to HIV Acquisition and AIDS Progression

Individual susceptibility to HIV-1 infection and the rate at which HIV disease progresses to clinical AIDS are significantly influenced by host genetic factors. Common human genetic variants play a crucial role, with GWAS identifying numerous single nucleotide polymorphisms (SNPs) associated with both HIV acquisition and disease progression.^[8] For instance, specific polymorphisms in the IL-18 gene promoter and variations in CXCL12 (SDF1) and CXCR4have been linked to HIV-1 infection susceptibility.^[8] Further studies have identified genetic variants within the AP3B1 gene (rs572880838 ) and PTPRA gene (rs6076463 ) as being associated with HIV-1C infection in specific populations.^[3] The NEO1 gene, specifically its promoter region SNPs such as rs9920504 , has also been associated with HIV infection, AIDS progression, and the development of AIDS-defining conditions like Kaposi’s sarcoma, Pneumocystis pneumonia (PCP), and B cell lymphoma.^[3] Beyond single variants, the influence of gene-gene interactions and larger genomic structures contributes to susceptibility. For example, segmental duplications within the CCL3L1 gene and genetic variations in the CCL18-CCL3-CCL4chemokine gene cluster have been shown to impact HIV-1 susceptibility, transmission, and the rate of AIDS disease progression.^[20]The substantial variation in disease progression, often spanning 9-10 years in untreated individuals, underscores the polygenic nature of AIDS, where multiple genetic loci collectively modulate the immune response and viral control.^[7] Research also indicates that the heritability of certain immune responses, such as resistance to TST/IGRA conversion, can be significant, suggesting a broader genetic influence on immune health relevant to HIV pathogenesis.^[17]

Gene-Environment Interactions and Epigenetic Modulation

The interplay between an individual’s genetic makeup and their environment profoundly influences AIDS pathogenesis. Genetic predispositions can be modulated by external factors, leading to varied outcomes in HIV acquisition and disease progression. For instance, while specific genetic variants may confer a degree of susceptibility or protection, the manifestation of their effects can depend on environmental exposures or lifestyle choices.^[3]This complex interaction highlights that genetic association studies alone may not fully capture the disease’s etiology, necessitating consideration of how host genome variability interacts with environmental triggers.

Emerging research emphasizes the role of epigenetic factors, such as DNA methylation and histone modifications, in modulating gene expression without altering the underlying DNA sequence. These early life influences and dynamic regulatory mechanisms can be affected by environmental factors and, in turn, impact an individual’s immune response and susceptibility to or progression of HIV/AIDS.^[3] Future studies incorporating diverse genome-level data, including epigenetic and transcriptome data, are crucial to comprehensively understand how these dynamic interactions contribute to HIV-1 acquisition, progression, and transmission.^[3]

Environmental and Lifestyle Influences on AIDS Development

Environmental and socioeconomic factors significantly contribute to the risk of HIV acquisition and the subsequent development of AIDS. Lifestyle choices, specific exposure routes, and broader societal conditions are critical determinants. Historically, populations at higher risk for HIV infection have included actively gay male participants, hemophiliacs receiving contaminated clotting factors, recipients of contaminated blood transfusions, and persons who inject drugs who shared HIV-contaminated syringes in urban settings.^[3] These examples highlight how specific behaviors and medical exposures act as direct pathways for viral transmission.

Beyond direct transmission routes, broader environmental and social factors, often unaccounted for in genetic studies, are recognized as important contributors to HIV-1 transmission and progression.^[3]These can include geographical influences, access to healthcare, and socioeconomic determinants that shape an individual’s risk of exposure and their ability to manage the infection effectively. While not a direct cause of AIDS, medication effects, such as hepatotoxicity induced by antiretroviral drugs alone or in combination with anti-tuberculosis drugs, represent a significant clinical consideration that can impact treatment adherence and overall health outcomes in individuals living with HIV.^[16]

Pathophysiology and Immune System Dysregulation in HIV Infection

aids, specifically in the context of HIV-1 infection, profoundly impacts the body’s immune system, leading to a state of chronic immune activation and decline. A critical indicator of this impact is theCD4/CD8 cell ratio, which reflects the balance between helper T cells (CD4+) and cytotoxic T cells (CD8+).^[21]In acute HIV infection, a disruption in this ratio is a hallmark, indicating the virus’s preferential targeting and depletion ofCD4+ cells, which are central to coordinating immune responses.^[21] Early initiation of antiretroviral therapy (ART) has been shown to influence this CD4/CD8ratio, underscoring the importance of timely intervention in preserving immune function and potentially altering disease progression.^[21]

Genetic and Epigenetic Influences on Disease Progression

Beyond direct viral effects, the progression of aids and its associated conditions involves complex genetic and epigenetic mechanisms. HIV-1 infection itself has been observed to accelerate biological aging, a phenomenon measurable through changes in the epigenetic clock.^[21]This suggests that the virus induces alterations in DNA methylation patterns, which are crucial epigenetic modifications influencing gene expression without changing the underlying DNA sequence.^[22]Genetic variants, such as single nucleotide polymorphisms (SNPs), often do not directly alter protein-coding sequences but instead affect disease risk by influencing regulatory elements likeCpG islands, transcription factor (TF)-binding sites, and miRNA-binding sites.^[22]These regulatory elements play a pivotal role in controlling when and where genes are expressed, thereby modulating cellular functions and disease susceptibility.^[22]

Molecular Pathways and Cellular Functions

The biological manifestations of aids are underpinned by intricate molecular and cellular pathways, involving a vast array of key biomolecules. Genes associated with various diseases, including those affecting the immune system, are often enriched in specific biological functions and networks.^[23] These networks are formed by direct interactions among critical proteins, enzymes, receptors, hormones, and transcription factors, which collectively govern cellular signaling, metabolic processes, and overall cellular functions.^[23] Understanding these interconnected pathways is essential for deciphering how genetic variations or viral infections disrupt normal homeostatic processes and lead to pathophysiological outcomes.^[23]

Systemic Consequences and Tissue-Specific Effects

The impact of aids extends beyond individual cells, manifesting as systemic consequences and specific effects across various tissues and organs. Genes associated with immune-related conditions, for instance, often exhibit higher expression levels in immune tissues and cells compared to non-immune tissues.^[22] The immune system itself is remarkably diverse, comprising numerous cell types with distinct functions and gene expression profiles that change across developmental stages.^[22]This tissue and cell-type specificity highlights how disruptions in particular molecular pathways or genetic regulatory networks can lead to localized effects within specific organs, as well as broader systemic consequences that contribute to the complex clinical picture of aids.^[22]

Cellular Signaling and Apoptotic Regulation

The progression of AIDS involves complex cellular signaling cascades that dictate immune cell fate and viral replication. HIV-1 infection can dysregulate critical intracellular pathways, such as the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which is targeted by the HIV-1 Tat protein to downregulate CREB transcription factor expression, particularly in neuronal cells.^[24] Conversely, certain host responses, like Prostaglandin E2 signaling, can inhibit HIV-1 replication in macrophages through the activation of protein kinase A (PKA).^[25] These pathways highlight the intricate balance between viral manipulation and host defense mechanisms, where receptor activation triggers cascades that ultimately influence gene expression and cellular function.

Apoptosis, or programmed cell death, is a hallmark of HIV-induced T cell depletion, and its biochemical mechanisms are critical to AIDS pathogenesis.^[26] HIV is known to induce a dual regulation of Bcl-2, a key protein in apoptosis regulation, which can lead to persistent infection inCD4+ T- or monocytic cell lines.^[27] Furthermore, F-box proteins, such as FBXO10, are implicated in controlling cell death and are induced by cellular stress, correlating with factors like lens epithelium-derived growth factor (LEDGF).^[28] The interplay of these signaling pathways and apoptotic regulators determines the survival of infected cells and the overall decline of the immune system.

Genetic Regulation and Immune Modulation

Host genetic factors play a significant role in susceptibility to HIV acquisition, viral replication, and disease progression, influencing the expression and function of genes involved in immune responses.^[29] For instance, genetic variations within the CCL18-CCL3-CCL4 chemokine gene cluster and the CCL3L1gene, which contains segmental duplications, can influence HIV-1 transmission and the rate of AIDS progression.^[30] These chemokines are crucial for recruiting immune cells and modulating inflammatory responses, thereby affecting the cellular environment for viral spread.

Beyond chemokine regulation, host genes associated with HIV replication in specific cell types have been identified, such as a single nucleotide polymorphism inDYRK1Alinked to HIV-1 replication in monocyte-derived macrophages.^[31] The presentation of HLA class I peptides is also a major genetic determinant affecting HIV-1 control, underscoring the importance of antigen presentation in adaptive immunity against the virus.^[32]Moreover, studies mapping cis- and trans-regulatory effects reveal patterns of cis regulatory variation that impact gene expression, potentially modulating host responses to HIV infection.^[33]

Metabolic Dysregulation and Cellular Stress Responses

HIV infection and its treatment can lead to significant metabolic dysregulation, affecting energy metabolism, biosynthesis, and catabolism, which contributes to various comorbidities in AIDS patients.^[15]Genes involved in glucose, carbohydrate, and lipid metabolism, such asFADS1, FADS2, GCKR, HNF1A, MLXIPL, PNPLA3, PPP1R3B, SLC2A2, and TRIB1, are implicated in these metabolic shifts.^[34] The liver, a central organ for metabolism, often experiences drug-induced hepatotoxicity with antiretroviral therapies, involving enzymes like cytochrome P450 (CYP) and N-acetyltransferase-2 (NAT2).^[16] Cellular stress responses, particularly endoplasmic reticulum (ER) stress, are also critical pathways in AIDS pathology and treatment-related toxicities. TheER to nucleus signaling-1 (ERN1) pathway and its components, including IRE1-JNK and GRP78/BiP, are activated during ER stress and contribute to cell death.^[35] Furthermore, glutathione metabolism, mediated by the glutathione S-transferasesupergene family, represents another pathway whose polymorphism can influence an individual’s response to oxidative stress and drug metabolism, both of which are highly relevant in the context of chronic HIV infection and antiretroviral therapy.^[36]

Systems-Level Integration and Disease Pathogenesis

The diverse pathways affected by HIV infection do not operate in isolation but are intricately interconnected through pathway crosstalk and network interactions, leading to emergent properties characteristic of AIDS. For instance, theMAP3K3 (mitogen-activated protein kinase-3) pathway, which contributes to interferon gamma production, is part of a broader network of inflammatory responses.^[16]Dysregulation within these integrated networks can lead to chronic inflammation and immune activation, which are central to AIDS pathogenesis and the development of non-AIDS comorbidities.

The systemic impact of HIV is evident in conditions like carotid atherosclerosis, which is consistently higher and occurs earlier in HIV-positive patients, suggesting a complex interplay of inflammatory and metabolic pathways.^[15] Similarly, HIV-associated neurocognitive disorder (HAND) involves neuroinflammatory processes where genes like NOD2 play a role in the inflammatory responses of microglia and astrocytes.^[21]These systems-level interactions, encompassing genetic predispositions, immune responses, and metabolic alterations, collectively contribute to the multifaceted progression of AIDS and offer multiple potential therapeutic targets beyond direct viral inhibition.

Ethical Oversight and Data Governance in Research

Genetic research pertaining to HIV/AIDS necessitates robust ethical oversight to ensure the protection of study participants and the integrity of scientific inquiry. Studies in this field are subject to rigorous review processes, often involving national and institutional ethics committees. For instance, research conducted in Uganda was approved by the National AIDS Research Committee, the Uganda National Council on Science and Technology, and an institutional review board, underscoring the multi-layered ethical review required for such sensitive investigations.^[17] These committees play a crucial role in evaluating research protocols, ensuring they meet ethical standards, and protecting the rights and welfare of individuals participating in genetic studies related to HIV.

Furthermore, the responsible management of genetic and clinical data is paramount. Data access committees, such as the WDMAC Institutional Data Access/Ethics Committee mentioned in the context of the Women’s Interagency HIV Study, establish strict criteria for researchers to access confidential data.^[37] This governance structure is vital for maintaining the privacy of individuals, preventing unauthorized data use, and fostering trust within research communities. Such meticulous data protection protocols are essential given the highly sensitive nature of both genetic information and HIV status, which could otherwise lead to significant personal and social repercussions.

Privacy and the Responsible Use of Genetic Information

The collection and analysis of genetic information in the context of HIV/AIDS raise significant privacy concerns. Genetic data are inherently unique to an individual and can reveal predispositions or characteristics that extend beyond the specific research focus. Therefore, ensuring the confidentiality of this information is critical to prevent potential harms, such as genetic discrimination in areas like employment, insurance, or social interactions. Robust data protection frameworks and careful anonymization or de-identification procedures are indispensable safeguards against such risks.

Health Equity and Global Research Collaboration

Research into the genetic determinants of HIV/AIDS often involves diverse populations across various geographic regions, highlighting critical considerations for health equity and global collaboration. Studies are conducted in numerous centers spanning the USA, Canada, the UK, Australia, and Uganda, reflecting the global burden of the epidemic and the necessity of inclusive research.^[38] This broad participation underscores the importance of ensuring that research benefits are equitably distributed and that findings are applicable across different demographic and cultural contexts.

The involvement of community health centers and specific patient cohorts, such as the Women’s Interagency HIV Study.^[37]further emphasizes the focus on populations significantly affected by HIV. Ethical considerations in such widespread research include addressing health disparities, ensuring equitable access to any potential advancements stemming from the research, and allocating resources fairly across participating regions. This holistic approach helps to ensure that scientific progress in understanding the genetic aspects of AIDS contributes to reducing health inequities rather than exacerbating them.

Frequently Asked Questions About Aids

These questions address the most important and specific aspects of aids based on current genetic research.

---

1. Why might I be more likely to get HIV than my friend?

Your genetic makeup can definitely influence your susceptibility to HIV. For example, some people have specific variants in genes like CXCL12 or CXCR4that might make them more vulnerable to infection. Conversely, a rare genetic change calledCCR5D32 can actually provide strong protection against HIV-1 acquisition. So, even with similar exposure, individual genetic differences play a significant role.

2. If I have HIV, why might it progress faster or slower for me?

The speed at which HIV progresses to AIDS can vary a lot between individuals, and your genes are a big part of that. Variants in your Major Histocompatibility Complex (MHC) region on chromosome 6, for instance, are known to influence how well your body controls HIV-1. Other genetic factors, like a specific locus at 1q41, can also affect how quickly the disease advances for you.

3. Could my family’s genes make me more vulnerable to HIV?

Yes, genetic factors related to HIV susceptibility and disease progression can run in families. If your family members have a history of either being more susceptible to HIV or experiencing faster progression, it’s possible you might share some of those genetic predispositions. This is why researchers study genetic variants to understand inherited risk.

4. Does my ethnic background affect my risk of getting HIV?

Research shows that genetic risk factors for HIV susceptibility can vary across different populations. For example, studies in African populations have identified specific genetic variants associated with HIV-1 infection or outcomes that might be more prevalent in certain ethnic groups. This highlights the importance of studying diverse populations to understand these differences.

5. Why might my body naturally resist HIV infection better than others?

Some people do have a natural genetic resistance to HIV infection. The most well-known example is a specific genetic variant calledCCR5D32. If you inherit two copies of this variant, it can make you highly resistant to HIV-1 infection, even with exposure. Other less common genetic variations might also contribute to a degree of natural resistance.

6. Can my own body’s genetics help me manage HIV better with treatment?

While antiretroviral therapy (ART) is crucial for managing HIV, your genetics can still play a role in how your body responds and how well you manage the virus. Genetic factors influence the rate of disease progression, and understanding these could potentially lead to more personalized treatment strategies in the future. However, ART remains the primary tool for viral suppression and immune preservation.

7. Can a DNA test tell me if I’m at higher risk for HIV?

Currently, while research identifies many genetic variants linked to HIV susceptibility and progression, a comprehensive DNA test isn’t routinely used to predict an individual’s specific “risk” for acquiring HIV in daily life. However, understanding these genetic factors through studies like genome-wide association studies is essential for developing future prevention strategies and personalized risk assessments.

8. Why does HIV turn into AIDS faster for some people?

The progression from HIV infection to clinical AIDS varies significantly, and your individual genetics are a key factor. Genes in the Major Histocompatibility Complex (MHC) region, for instance, influence how effectively your immune system can control the virus. Other genetic variants, such as those at the 1q41 locus, have also been linked to the speed of disease progression, explaining why some individuals may progress more rapidly than others.

9. If my partner has HIV, do my genes affect my risk of getting it?

Yes, your individual genetic makeup can influence your susceptibility to acquiring HIV, even with exposure from a partner. Specific genetic variants in genes like CXCL12 or CXCR4 have been implicated in HIV-1 susceptibility. A notable example is the CCR5D32variant, which can provide significant protection against infection for individuals who carry two copies of it.

10. Could my unique genes lead to better personalized HIV treatment for me?

Absolutely. While current antiretroviral therapy (ART) is highly effective, ongoing research, including genome-wide association studies, aims to understand how genetic resistance and susceptibility vary among individuals. This knowledge could eventually inform the development of more personalized prevention strategies, vaccine designs, and potentially even tailored treatment approaches that are optimized based on your specific genetic profile.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] McLaren, P. J. et al. “Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls.” PLoS Pathog, vol. 9, no. 8, 2013, e1003573.

[2] Johnson, E. O., et al. “Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: a genome-wide association study.” PLoS One, 2015.

[3] Shevchenko, A. K. et al. “Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.”Proc Natl Acad Sci U S A, vol. 118, no. 48, 2021, e2107830118.

[4] Wellcome Trust Case Control Consortium. “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.” Nature, 2007.

[5] Schurz, H, et al. “Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture.”Elife, 2024.

[6] Fellay, J. et al. “Common genetic variation and the control of HIV-1 in humans.” PLoS Genet, vol. 6, no. 1, 2010.

[7] Herbeck, J. T. et al. “Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS.”J Infect Dis, vol. 201, no. 1, 2010, pp. 116–24.

[8] Petrovski, S. et al. “Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population.” AIDS, vol. 25, no. 1, 2011, pp. 49-57.

[9] Petros, Z. “Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.”OMICS. PMID: 28388302.

[10] Herbeck, J. T. “Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS.”J Infect Dis. PMID: 20064070.

[11] “The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.”Am J Epidemiol, 1987, pp. 310–318.

[12] Centers for Disease Control and Prevention. “1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.”MMWR Recomm Rep, 1992, pp. 1–19.

[13] Moore, C. B. “Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.”Open Forum Infect Dis. PMID: 25884002.

[14] UNAIDS. “2008 Report on the global AIDS epidemic.” 2008.

[15] Shrestha, S. et al. “A genome-wide association study of carotid atherosclerosis in HIV-infected men.”AIDS, vol. 24, no. 2, pp. 289-296, 2010.

[16] Petros, Z. et al. “Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.”OMICS, vol. 21, no. 4, 2017, pp. 200–208.

[17] McHenry ML et al. “Resistance to TST/IGRA conversion in Uganda: Heritability and Genome-Wide Association Study.” EBioMedicine, vol. 74, 2021, p. 103720.

[18] Moore, C. B. “Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.”Open Forum Infect Dis, vol. 2, no. 2, 2014.

[19] Muñoz, A. et al. “The incubation period of AIDS.”AIDS, vol. 11, 1997, pp. S69–S76. PMID: 9451969.

[20] Melzer, D. et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, e1000072.

[21] Jia P, et al. “Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.” Am J Med Genet B Neuropsychiatr Genet, vol. 174, no. 5, 2017, pp. 439-448.

[22] Li YR, et al. “Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.” Nat Med, vol. 22, no. 9, 2016, pp. 1026-1033.

[23] Waage J, et al. “Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis.”Nat Genet, vol. 50, no. 8, 2018, pp. 1088-1096.

[24] Zauli, G. et al. “HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway.”FASEB J, vol. 15, no. 2, pp. 483-491, 2001.

[25] Hayes, M. M. et al. “Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A.” Cell Immunol, vol. 215, no. 1-2, pp. 61-71, 2002.

[26] Selliah, N., and Finkel, T. H. “Biochemical mechanisms of HIV induced T cell apoptosis.” Cell Death Differ, vol. 8, no. 2, pp. 121-125, 2001.

[27] Aillet, F. et al. “Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines.”J Virol, vol. 72, 1998.

[28] Chiorazzi, M. et al. “Related F-box proteins control cell death.” Cell Death Differ, 2013.

[29] An, P., and Winkler, C. A. “Host genes associated with HIV/AIDS: advances in gene discovery.”Trends, 2010.

[30] Gonzalez, E. et al. “The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.”Science, vol. 307, no. 5715, pp. 1434-1440, 2005.

[31] Bol, S. M. et al. “Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages.”PLoS One, 2011.

[32] Leger, P. D. et al. “Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.”J Neurovirol, vol. 20, no. 2, pp. 190-199, 2014.

[33] Grundberg, E. et al. “Mapping cis- and trans-regulatory.” Nature Genetics, 2012.

[34] Chambers, J. C. et al. “Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.” Nat Genet, 2011.

[35] Chen, L. et al. “Cab45S inhibits the ER stress-induced IRE1-JNK pathway and apoptosis via GRP78/BiP.” Cell Death Dis, vol. 5, e1219, 2014.

[36] Ketterer, B. et al. “The human glutathione S-transferase supergene family, its polymorphism, and its.” Arch Toxicol Suppl, vol. 15, pp. 3-17, 1992.

[37] Shendre A et al. “Genome-wide admixture and association study of subclinical atherosclerosis in the Women’s Interagency HIV Study (WIHS).”PLoS One, vol. 12, no. 12, 2017, e0189912.

[38] Pereyra F et al. “The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.”Science, vol. 330, no. 6010, 2010, pp. 1551-1557.